Literature DB >> 9548454

Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation.

M G Levisetti1, P A Padrid, G L Szot, N Mittal, S M Meehan, C L Wardrip, G S Gray, D S Bruce, J R Thistlethwaite, J A Bluestone.   

Abstract

Ag-specific T cell activation requires a CD28-mediated costimulatory interaction. This observation has suggested novel approaches to suppress donor-specific immunity, including the use of soluble CD28 antagonists, such as CTLA4Ig, which suppresses transplant rejection in small animal models. In this study, CTLA4Ig therapy was examined in a non-human primate model of allogeneic pancreatic islet transplantation. Two of five CTLA4Ig-treated monkeys showed prolonged graft survival, which correlated with donor-specific hyporesponsiveness in vitro. Humoral responses to the transplanted tissue were suppressed in all treated animals. These results suggest that CTLA4Ig is effective in suppressing both humoral and cellular immune responses in a non-human primate model of allogeneic transplantation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9548454

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  52 in total

1.  Prevention of T-cell activation by rhCTLA4-Ig and anti-CD40L monoclonal antibody results in indefinite islet allograft survival.

Authors:  C Rastellini; A Salam; R Kuddus; A Aitouche; V Subbotin; M Braun; R Leach; R Peach; J J Fung; T E Starzl; A S Rao
Journal:  Transplant Proc       Date:  1999 Feb-Mar       Impact factor: 1.066

Review 2.  Experimental corneal allograft rejection.

Authors:  Bryan M Gebhardt; Weiyun Shi
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

3.  New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs.

Authors:  Masayuki Sho; Sigrid E Sandner; Nader Najafian; Alan D Salama; Victor Dong; Akira Yamada; Koji Kishimoto; Hiroshi Harada; Isabela Schmitt; Mohamed H Sayegh
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

4.  Use of CTLA4Ig for induction of mixed chimerism and renal allograft tolerance in nonhuman primates.

Authors:  Y Yamada; T Ochiai; S Boskovic; O Nadazdin; T Oura; D Schoenfeld; K Cappetta; R-N Smith; R B Colvin; J C Madsen; D H Sachs; G Benichou; A B Cosimi; T Kawai
Journal:  Am J Transplant       Date:  2014-11-13       Impact factor: 8.086

5.  CD28 blockade induces division-dependent downregulation of interleukin-2 receptor alpha.

Authors:  Mandy L Ford; Linda L Stempora; Christian P Larsen
Journal:  Transpl Immunol       Date:  2010-11-10       Impact factor: 1.708

Review 6.  Immunotherapy for De Novo renal transplantation: what's in the pipeline?

Authors:  Helio Tedesco Silva; Paula Pinheiro Machado; Claudia Rosso Felipe; Jose Osmar Medina Pestana
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 7.  Optimising islet engraftment is critical for successful clinical islet transplantation.

Authors:  O Korsgren; T Lundgren; M Felldin; A Foss; B Isaksson; J Permert; N H Persson; E Rafael; M Rydén; K Salmela; A Tibell; G Tufveson; B Nilsson
Journal:  Diabetologia       Date:  2007-11-27       Impact factor: 10.122

8.  PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection.

Authors:  Katsunori Tanaka; Monica J Albin; Xueli Yuan; Kazuhiro Yamaura; Antje Habicht; Takaya Murayama; Martin Grimm; Ana Maria Waaga; Takuya Ueno; Robert F Padera; Hideo Yagita; Miyuki Azuma; Tahiro Shin; Bruce R Blazar; David M Rothstein; Mohamed H Sayegh; Nader Najafian
Journal:  J Immunol       Date:  2007-10-15       Impact factor: 5.422

Review 9.  T-cell costimulatory blockade in organ transplantation.

Authors:  Jonathan S Maltzman; Laurence A Turka
Journal:  Cold Spring Harb Perspect Med       Date:  2013-12-01       Impact factor: 6.915

Review 10.  Profile of belatacept and its potential role in prevention of graft rejection following renal transplantation.

Authors:  Gaurav Gupta; Karl L Womer
Journal:  Drug Des Devel Ther       Date:  2010-12-01       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.